Private Advisor Group LLC Sells 285 Shares of Biohaven Ltd. (NYSE:BHVN)

Private Advisor Group LLC trimmed its position in Biohaven Ltd. (NYSE:BHVN) by 3.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,364 shares of the company’s stock after selling 285 shares during the period. Private Advisor Group LLC’s holdings in Biohaven were worth $368,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Cadent Capital Advisors LLC bought a new position in Biohaven in the 3rd quarter valued at $1,771,000. nVerses Capital LLC bought a new position in Biohaven in the 3rd quarter valued at $50,000. Creative Planning boosted its holdings in Biohaven by 57.9% in the 3rd quarter. Creative Planning now owns 18,209 shares of the company’s stock valued at $910,000 after purchasing an additional 6,674 shares during the period. Exchange Traded Concepts LLC boosted its holdings in Biohaven by 15.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 19,893 shares of the company’s stock valued at $994,000 after purchasing an additional 2,728 shares during the period. Finally, Cypress Wealth Services LLC bought a new stake in shares of Biohaven during the 3rd quarter worth $224,000. 88.78% of the stock is owned by institutional investors.

Insider Buying and Selling at Biohaven

In other news, Director John W. Childs acquired 21,052 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The shares were purchased at an average price of $47.50 per share, for a total transaction of $999,970.00. Following the completion of the transaction, the director now owns 21,052 shares of the company’s stock, valued at $999,970. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Gregory Bailey acquired 5,000 shares of the firm’s stock in a transaction on Tuesday, September 24th. The shares were purchased at an average price of $44.19 per share, for a total transaction of $220,950.00. Following the completion of the transaction, the director now owns 1,620,071 shares of the company’s stock, valued at $71,590,937.49. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John W. Childs acquired 21,052 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was purchased at an average price of $47.50 per share, for a total transaction of $999,970.00. Following the transaction, the director now directly owns 21,052 shares of the company’s stock, valued at approximately $999,970. The disclosure for this purchase can be found here. Corporate insiders own 16.00% of the company’s stock.

Biohaven Stock Up 2.7 %

Biohaven stock opened at $51.40 on Wednesday. The company has a market capitalization of $4.86 billion, a PE ratio of -5.47 and a beta of 1.31. The firm has a fifty day simple moving average of $46.04 and a two-hundred day simple moving average of $40.19. Biohaven Ltd. has a twelve month low of $26.80 and a twelve month high of $62.21.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($3.64) earnings per share for the quarter, missing the consensus estimate of ($1.72) by ($1.92). As a group, equities analysts expect that Biohaven Ltd. will post -8.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on BHVN. Robert W. Baird lifted their price objective on shares of Biohaven from $58.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. JPMorgan Chase & Co. lifted their price objective on shares of Biohaven from $55.00 to $68.00 and gave the stock an “overweight” rating in a report on Thursday, October 3rd. HC Wainwright reaffirmed a “buy” rating and set a $59.00 price objective on shares of Biohaven in a report on Tuesday, September 24th. Leerink Partners lifted their price objective on shares of Biohaven from $55.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. Finally, Jefferies Financial Group began coverage on shares of Biohaven in a report on Monday, September 16th. They set a “buy” rating and a $57.00 price objective for the company. Thirteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $61.92.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.